Technical analysis of Contineum Therapeutics, Inc. (CTNM): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Price Performance
| 1 month | -0.47% |
| 3 months | +20.87% |
| Year-to-date | +26.27% |
| 1 year | +16.48% |
52-Week Range
| 52-week High | $17.79 |
| 52-week Low | $8.60 |
| Avg Volume (90d) | 375K |
Technical Indicators
| SMA 50 | $15.30 |
| SMA 200 | $13.63 |
| Beta | 1.39 |
| 30-day Volatility (annualised) | 63.2% |
| Price vs SMA 50 | -5.7% |
| Price vs SMA 200 | +5.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $11.01 | |
| 2025-11 | $11.07 | +0.5% |
| 2025-12 | $11.43 | +3.3% |
| 2026-01 | $14.26 | +24.8% |
| 2026-02 | $15.34 | +7.6% |
| 2026-03 | $13.06 | -14.9% |
| 2026-04 | $12.82 | -1.8% |
| 2026-05 | $13.49 | +5.2% |
| 2026-06 | $16.39 | +21.5% |
| 2026-07 | $15.49 | -5.5% |
| 2026-08 | $16.24 | +4.8% |
| 2026-09 | $14.43 | -11.1% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | $-0.03 | $261M |
| 2026-09-14 | $0.02 | $195M |
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | $-0.03 | $278M |
| 2026-09-14 | $-0.93 | $268M |
Price
| Price | $13.76 |
| Market Cap | $518M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.04 |
| EV / EBITDA | -9.40 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 37.17 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 11.55 |